research COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
Search
for
Sort by
Research
330-360 / 1000+ results research The anticonvulsant effects of progesterone and its metabolites
5alpha-DHP may be a safe, effective treatment for certain seizures without causing sedation.
research Clinical efficacy and safety of low‐dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism
Low-dose flutamide helps reduce excessive hair growth and is even more effective with birth control, without bad effects on blood fats.
research Diagnosis dan Tata Laksana Frambusia
Improving medical training is key to eradicating frambusia by 2030.
research Matrix effects and application of matrix effect factor
Matrix effects in LC-MS can be managed but not completely avoided.
research Diphenylcyclopropenone: An Important Agent Known to Cause Depigmentation / Reply
research Protoporphyrin IX: the Good, the Bad, and the Ugly
Protoporphyrin IX is useful in cancer treatment but can cause health problems if not properly regulated.
research METYRAPONE AS A BRIDGING THERAPY IN FLORID CUSHING’S DISEASE PATIENT PRIOR TO PITUITARY ADENOMECTOMY
Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.
research New Progesterone Esters as 5.ALPHA.-Reductase Inhibitors.
Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
research Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine — a retrospective comparison study of North Indian patients with refractory epilepsy
Levetiracetam often causes behavioral issues, while oxcarbazepine is more likely to cause sleepiness in epilepsy patients.
research The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial
Both injectable contraceptives lower testosterone and SHBG levels, with NET-EN having a greater effect than DMPA-IM.
research Finasteride inhibits the disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis
Finasteride worsens seizures in epilepsy rats and speeds up epileptogenesis in mice.
research Early postnatal inhibition of neurosteroid synthesis changes the later-life adverse outcome of neonatal asphyxia in rats
Finasteride reduced seizures and prevented cognitive issues in rats after neonatal asphyxia but increased anxiety later.
research Novel 5α-Reductase Inhibitors: Synthesis, Structure−Activity Studies, and Pharmacokinetic Profile of Phenoxybenzoylphenyl Acetic Acids
A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
research Cyproterone Acetate Quantification in Human Plasma by High-performance Liquid Chromatography Coupled to Atmospheric Pressure Photoionization Tandem Mass Spectrometry
The method accurately measures cyproterone acetate in plasma, showing no significant difference between two formulations.
research Monilethrix treated with the oral retinoid Ro 10-9359 (Tigason)
Tigason improved hair growth in a boy with monilethrix without side effects.
research Efficacy and tolerability of oral bicalutamide in forty postmenopausal women with female pattern hair loss: a retrospective study
Bicalutamide may improve hair growth in postmenopausal women with mild side effects.
research 3a-Phenylhexahydropentalene-1,6-dione
A rigid compound with a common structural motif was successfully synthesized.
research Finasteride Blocks the Reduction in Ictal Activity Produced by Exogenous Estrous Cyclicity
research [PRACTICAL EXPERIENCES WITH OVULATION INHIBITION].
Ovulation inhibitors effectively treat menstrual issues and improve fertility but can have side effects.
research 549 Temporary cell cycle arrest in human scalp hair follicles and their epithelial stem cells by ALRN-6924: A novel strategy to selectively protect p53-wildtype cells against paclitaxel-induced alopecia
ALRN-6924 may prevent hair loss caused by chemotherapy.
research Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health
Current drug safety systems fail to detect long-term side effects, leading to preventable health issues.
research Abstract P5-11-11: A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)
Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
research Long-term toxicologic and tumorigenesis studies on an oral contraceptive agent in albino rats
research 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
research Inhibiting Biosynthesis and/or Metabolism of Progestins in the Ventral Tegmental Area Attenuates Lordosis of Rats in Behavioural Oestrus
Blocking certain brain processes reduces mating behavior in female rats.
research Valproic acid in childhood epilepsy: anticonvulsive efficacy in relation to its plasma levels.
Valproic acid is effective for controlling seizures in children, especially as a single treatment, with some side effects.
research Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.